Back to Headlines
Business
May 27, 2026
Analyzed by GPT OSS 120B

BioOrbit Launches Box‑E to Grow Ultra‑Pure Cancer Drug Crystals in Space

AI Summary
UK biotech startup **BioOrbit** sent its microgravity‑crystallisation unit **Box‑E** to the International Space Station on a **SpaceX** flight on 15 May. Backed by a **£9.8 million** Series A round and a **£250,000** UK Space Agency contract, the company aims to produce self‑injectable cancer drugs that could cut hospital visits and save health systems billions.

On 15 May, **BioOrbit** launched its compact **Box‑E** payload aboard a **SpaceX** rocket, beginning a six‑week orbital trial to grow ultra‑pure protein crystals for self‑injectable cancer therapies.

Box‑E’s Orbital Test: Microgravity Enables Ultra‑Pure Protein Crystals

The microwave‑sized unit will float aboard the International Space Station, where microgravity eliminates the disruptive effects of Earth’s gravity on crystal formation. The resulting crystals are more stable, allowing drug formulations that are impossible to achieve on the ground.

  • Mission duration: ~6 weeks in orbit
  • Target output: thousands of litres of fluid per box per year
  • Goal: Produce cancer‑drug crystals that can be stored in a fridge and self‑injected

£9.8 Million Funding Round and UK Space Agency Contract

Last month **BioOrbit** closed a **£9.8 million** Series A round led by **LocalGlobe** and **Breega**, earmarked for the orbital test and scaling of the hardware. Earlier in March the company secured a **£250,000** contract from the UK Space Agency to manufacture drugs in microgravity.

Potential Disruption of Cancer Treatment Delivery

Current immunotherapies such as Merck’s **Keytruda** require lengthy IV infusions in hospitals. By crystallising the active protein, **Box‑E** could enable high‑concentration, low‑viscosity formulations suitable for pen‑injectors, reducing treatment time from hours to minutes and extending shelf‑life.

Roadmap to Commercialisation and Market Size

**BioOrbit** projects that, if orbital tests succeed, multiple **Box‑E** units could be stacked to meet the demand of a blockbuster drug within a handful of boxes. The company estimates a market of **$22.7 trillion** for in‑space manufacturing across sectors, with pharmaceuticals a key segment. Clinical trials and regulatory approval are expected to take at least five years before the new formulations reach patients.

Future Outlook for Space‑Based Pharma

Beyond cancer, the crystallisation platform could be applied to the roughly 70 % of top‑selling drugs that are currently administered intravenously. Partnerships with major pharma groups are already being explored, and competitors such as **Varda Space Industries** are also pursuing in‑orbit drug processing, signaling a burgeoning industry.